Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: THC ~5% Clear all
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cannabis Use, Cognition, and the Endocannabinoid System in HIV

NCT04883255
View directory record Official record
Conditions
HIV-1-infection
Interventions
10 mg Δ9-tetrahydrocannabinol (THC), 600 mg cannabidiol (CBD), Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Phase 1 Interventional

Interleukin-2 Treatment for Wiskott-Aldrich Syndrome

NCT00774358
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome (WAS), X-linked Thrombocytopenia
Interventions
Interleukin-2
Drug
Lead sponsor
Soma Jyonouchi
Other
Eligibility
24 Months and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)

NCT05101122
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Dosing 1: Atomoxetine, AD313
Drug
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 10, 2026, 4:22 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults

NCT05906511
View directory record Official record
Conditions
Pain, Tolerance, Oral vs Vaporized THC, Abuse Liability
Interventions
Dronabinol 5 MG, Dronabinol 10 MG, 2mg Purified THC in an ethanolic solution, 4mg Purified THC in an ethanolic solution, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 10, 2026, 4:22 PM EDT
Not listed Phase 2 Interventional

Cannabinoid Tablets for the Treatment of Pain From Osteoarthritis of the Knee

NCT04992962
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
CBD/CBN, CBD/THC, Placebo
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Sep 10, 2026, 4:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

Warrior CARE: Cannabis Behavioral Health

NCT06381180
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Cannabis Use, Suicide, Veterans, Marijuana
Interventions
Tetrahydrocannabinol, Cannabidiol, Placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
19 Years to 69 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?

NCT01964404
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder
Interventions
Marijuana, Dronabinol, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
2
States / cities
Lebanon, New Hampshire • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 10, 2026, 4:22 PM EDT
Completed No phase listed Observational

Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)

NCT03399461
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome
Interventions
Patient Interview guide, Caregiver interview guide, Sociodemographic questionnaire, Pediatric quality of life (PedsQL) questionnaire, Clinical questionnaire
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 30 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Collegeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Marijuana on Symptoms of OCD

NCT03274440
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Cannabis, Placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

NCT01887301
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Sativex
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Anaheim, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Influence of Edible Marijuana on Endurance Exercise Performance

NCT05192239
View directory record Official record
Conditions
Endurance Exercise
Interventions
THC 5, Placebo
Drug
Lead sponsor
Christopher Bell
Other
Eligibility
21 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease

NCT02818777
View directory record Official record
Conditions
Parkinson's Disease
Interventions
cannabidiol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 10, 2026, 4:22 PM EDT
Active, not recruiting Not applicable Interventional

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

NCT01652092
View directory record Official record
Conditions
SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
Interventions
Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Melphalan, Alemtuzumab 0.2 mg, Fludarabine phosphate 30 mg, MESNA
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 50 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Phase 4 Interventional Results available

Dronabinol in Total Knee Arthroplasty (TKA)

NCT04734080
View directory record Official record
Conditions
Total Knee Arthroplasty, Opioid Use
Interventions
Dronabinol 5mg Cap, Placebo oral tablet
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Phase 3 Interventional Results available

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

NCT01262651
View directory record Official record
Conditions
Pain, Advanced Cancer
Interventions
Nabiximols, Placebo (GA-0034)
Drug
Lead sponsor
GW Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
25
States / cities
Phoenix, Arizona • El Cajon, California • Gilroy, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Dronabinol Naltrexone Treatment for Opioid Dependence

NCT01024335
View directory record Official record
Conditions
Opioid Dependence
Interventions
injectable naltrexone and dronabinol, Naltrexone and placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Sep 10, 2026, 4:22 PM EDT
Recruiting Phase 2 Interventional

DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.

NCT07635563
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 7.5 mg dronabinol + 375 mg acetazolamide, Placebo: Negative control
Drug
Lead sponsor
Incannex Healthcare Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Chula Vista, California • Brandon, Florida • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers

NCT00743119
View directory record Official record
Conditions
Pain Threshold, Mood
Interventions
Placebo capsules, Inactive marijuana (0% THC), Low dose Dronabinol, High dose Dronabinol, Low THC marijuana, High THC marijuana
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 10, 2026, 4:22 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

NCT04615949
View directory record Official record
Conditions
COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions
Cannabidiol, pharmaceutically produced with < 5 ppm THC, Placebo
Drug
Lead sponsor
Cardiol Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Phoenix, Arizona • Cutler Bay, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 10, 2026, 4:22 PM EDT
Suspended Phase 2 Interventional

Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment

NCT05427630
View directory record Official record
Conditions
Migraine, Cannabis, THC
Interventions
THC ~2.5%, THC ~5%, THC ~10%, Sham Cannabis
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease

NCT01771731
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cannabis
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Sep 10, 2026, 4:22 PM EDT
Withdrawn Phase 2 Interventional

The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia

NCT02608931
View directory record Official record
Conditions
Nausea, Vomiting, Familial Dysautonomia
Interventions
Dronabinol, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis

NCT05180240
View directory record Official record
Conditions
Acute Myocarditis
Interventions
CardiolRx
Drug
Lead sponsor
Cardiol Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 10, 2026, 4:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cannabis Impairment Detection Application (CIDA)

NCT04230460
View directory record Official record
Conditions
Driving Under the Influence, Marijuana Intoxication, Alcohol Intoxication
Interventions
Cannabis (THC) (Inhaled) Placebo, Cannabis (High% THC) (Inhaled), Cannabis (Very High% THC) (Inhaled), Alcohol (oral)
Drug
Lead sponsor
Advanced Brain Monitoring, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 10, 2026, 4:22 PM EDT